c-Met-话题@MedSci - 梅斯（MedSci）

#c-Met#

11篇内容 | 1192人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2218403, encodeId=8aa82218403f1, content=<a href='/topic/show?id=2fdc99e222d' target=_blank style='color:#2F92EE;'>#非酒精性脂肪性肝炎#</a> <a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a> <a href='/topic/show?id=253781363b0' target=_blank style='color:#2F92EE;'>#肝细胞生长因子#</a>, objectTitle=iScience：一种新的人工肝细胞生长因子模拟分子有望缓解非酒精性脂肪性肝炎, objectType=article, longId=837537, objectId=770e83e53757, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/20240803/1722680776479_2185383.png, objectUrl=/article/show_article.do?id=770e83e53757, replyNumber=0, likeNumber=42, createdTime=2024-08-04, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1722972, encodeId=846a1e2297291, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, objectTitle=Clin Cancer Res：转移性去势抵抗性前列腺癌c-MET和雄激素受体双重阻断:恩扎鲁胺和克唑替尼联合应用的一期研究, objectType=article, longId=201364, objectId=cf922013647f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf922013647f, replyNumber=0, likeNumber=66, createdTime=2021-05-21, rootId=0, userName=天堂的云, userId=805733331422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf922013647f, moduleTitle=Clin Cancer Res：转移性去势抵抗性前列腺癌c-MET和雄激素受体双重阻断:恩扎鲁胺和克唑替尼联合应用的一期研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cf922013647f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1722971, encodeId=93b71e229716d, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, objectTitle=Nat Commun：在膀胱癌进展中c-Met激活能够引起TGFβ受体调控网络的建立, objectType=article, longId=181751, objectId=48f5181e51a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48f5181e51a4, replyNumber=0, likeNumber=69, createdTime=2020-05-02, rootId=0, userName=天堂的云, userId=805733331422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48f5181e51a4, moduleTitle=Nat Commun：在膀胱癌进展中c-Met激活能够引起TGFβ受体调控网络的建立, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=48f5181e51a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1722970, encodeId=c0121e2297082, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, objectTitle=Clinica Chimica Acta：microRNA-34a通过下调c-Met抑制人晶状体上皮细胞的增殖和迁移, objectType=article, longId=179870, objectId=34301e9870c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34301e9870c6, replyNumber=0, likeNumber=78, createdTime=2020-09-05, rootId=0, userName=天堂的云, userId=805733331422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34301e9870c6, moduleTitle=Clinica Chimica Acta：microRNA-34a通过下调c-Met抑制人晶状体上皮细胞的增殖和迁移, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=34301e9870c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1722969, encodeId=2d831e2296914, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, objectTitle=CLIN CANCER RES：HGF/c-MET通路调节非小细胞肺癌VEGFR抑制剂耐药, objectType=article, longId=113909, objectId=a3b411390971, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3b411390971, replyNumber=0, likeNumber=73, createdTime=2018-03-10, rootId=0, userName=天堂的云, userId=805733331422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3b411390971, moduleTitle=CLIN CANCER RES：HGF/c-MET通路调节非小细胞肺癌VEGFR抑制剂耐药, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a3b411390971)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1722968, encodeId=f08b1e2296895, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, objectTitle=ASCO 2016：c-Met抑制剂Tepotinib 用于亚洲晚期肝癌现优势, objectType=article, longId=70430, objectId=b020e043048, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b020e043048, replyNumber=0, likeNumber=71, createdTime=2016-10-10, rootId=0, userName=天堂的云, userId=805733331422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b020e043048, moduleTitle=ASCO 2016：c-Met抑制剂Tepotinib 用于亚洲晚期肝癌现优势, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b020e043048)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1722967, encodeId=84191e2296704, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, objectTitle=Gastric Cancer：HER2，EGFR及c-Met状态对晚期胃癌患者总存活的预后影响, objectType=article, longId=47688, objectId=9d5b4e68878, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d5b4e68878, replyNumber=0, likeNumber=70, createdTime=2015-07-03, rootId=0, userName=天堂的云, userId=805733331422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d5b4e68878, moduleTitle=Gastric Cancer：HER2，EGFR及c-Met状态对晚期胃癌患者总存活的预后影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9d5b4e68878)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1722964, encodeId=0ba11e229643c, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, objectTitle=ASCO 2014：亚洲进展期肝癌患者口服c-Met抑制剂MSC2156119J单药与索拉非尼比较的Ib/II期试验, objectType=article, longId=35648, objectId=35c7356487a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35c7356487a, replyNumber=0, likeNumber=79, createdTime=2015-01-24, rootId=0, userName=天堂的云, userId=805733331422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35c7356487a, moduleTitle=ASCO 2014：亚洲进展期肝癌患者口服c-Met抑制剂MSC2156119J单药与索拉非尼比较的Ib/II期试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=35c7356487a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1722966, encodeId=3ccf1e22966ed, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, objectTitle=CSCO 2014：c-MET肿瘤通路论坛——价值已被认识，治疗仍待研究, objectType=article, longId=40494, objectId=e65440494b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e65440494b6, replyNumber=0, likeNumber=89, createdTime=2014-12-16, rootId=0, userName=天堂的云, userId=805733331422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e65440494b6, moduleTitle=CSCO 2014：c-MET肿瘤通路论坛——价值已被认识，治疗仍待研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e65440494b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1722965, encodeId=1a031e22965c2, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, objectTitle=ASCO 2014：c-met抑制剂INC280联合吉非替尼治疗EGFR-TKI耐药的NSCLC取得较好疗效, objectType=article, longId=35735, objectId=b22c35e35e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b22c35e35e3, replyNumber=0, likeNumber=81, createdTime=2014-11-22, rootId=0, userName=天堂的云, userId=805733331422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b22c35e35e3, moduleTitle=ASCO 2014：c-met抑制剂INC280联合吉非替尼治疗EGFR-TKI耐药的NSCLC取得较好疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b22c35e35e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1722963, encodeId=3cbc1e2296310, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, objectTitle=ASCO 2014：克唑替尼治疗 c-MET-基因扩增型晚期NSCLC, objectType=article, longId=35083, objectId=73f63508326, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73f63508326, replyNumber=0, likeNumber=75, createdTime=2014-07-15, rootId=0, userName=天堂的云, userId=805733331422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73f63508326, moduleTitle=ASCO 2014：克唑替尼治疗 c-MET-基因扩增型晚期NSCLC, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=73f63508326)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1722962, encodeId=bb5b1e229621f, content=<a href='/topic/show?id=196d38e720' target=_blank style='color:#2F92EE;'>#c-Met#</a>, objectTitle=Diabetes：HGF/c-Met信号通路为女性妊娠糖尿病的治疗带来希望, objectType=article, longId=4379, objectId=61c543e956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61c543e956, replyNumber=0, likeNumber=69, createdTime=2013-02-09, rootId=0, userName=天堂的云, userId=805733331422, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61c543e956, moduleTitle=Diabetes：HGF/c-Met信号通路为女性妊娠糖尿病的治疗带来希望, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=61c543e956)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

c-Met

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#非酒精性脂肪性肝炎# #c-Met# #肝细胞生长因子#

2024-08-04发表于上海

天堂的云 (审核中...)

前往app查看评论内容

#c-Met#

Clin Cancer Res：转移性去势抵抗性前列腺癌c-MET和雄激素受体双重阻断:恩扎鲁胺和克唑替尼联合应用的一期研究

2021-05-21

天堂的云 (审核中...)

前往app查看评论内容

#c-Met#

Nat Commun：在膀胱癌进展中c-Met激活能够引起TGFβ受体调控网络的建立

2020-05-02

天堂的云 (审核中...)

前往app查看评论内容

#c-Met#

Clinica Chimica Acta：microRNA-34a通过下调c-Met抑制人晶状体上皮细胞的增殖和迁移

2020-09-05

天堂的云 (审核中...)

前往app查看评论内容

#c-Met#

CLIN CANCER RES：HGF/c-MET通路调节非小细胞肺癌VEGFR抑制剂耐药

2018-03-10

天堂的云 (审核中...)

前往app查看评论内容

#c-Met#

ASCO 2016：c-Met抑制剂Tepotinib 用于亚洲晚期肝癌现优势

2016-10-10

天堂的云 (审核中...)

前往app查看评论内容

#c-Met#

Gastric Cancer：HER2，EGFR及c-Met状态对晚期胃癌患者总存活的预后影响

2015-07-03

天堂的云 (审核中...)

前往app查看评论内容

#c-Met#

ASCO 2014：亚洲进展期肝癌患者口服c-Met抑制剂MSC2156119J单药与索拉非尼比较的Ib/II期试验

2015-01-24

天堂的云 (审核中...)

前往app查看评论内容

#c-Met#

CSCO 2014：c-MET肿瘤通路论坛——价值已被认识，治疗仍待研究

2014-12-16

天堂的云 (审核中...)

前往app查看评论内容

#c-Met#

ASCO 2014：c-met抑制剂INC280联合吉非替尼治疗EGFR-TKI耐药的NSCLC取得较好疗效

2014-11-22

天堂的云 (审核中...)

前往app查看评论内容

#c-Met#

ASCO 2014：克唑替尼治疗 c-MET-基因扩增型晚期NSCLC

2014-07-15

天堂的云 (审核中...)

前往app查看评论内容

#c-Met#

Diabetes：HGF/c-Met信号通路为女性妊娠糖尿病的治疗带来希望

2013-02-09

科室
- - 订阅+
  - 更多科室
工具
服务